The Insider Activity Report For Laboratory Corporation of America Holdings (LH): Who’s Selling?

Laboratory Corporation of America Holdings (NYSE:LH) finished Friday with an addition of $2.34 to close at $282.15, an upside of 0.84 percent. An average of 474,860 shares of common stock have been traded in the last five days. There was a gain of $10.55 in the past week, and it reached a new high 39 times over the past 12 months. The last 20 days have seen an average of 522,430 shares traded, while the 50-day average volume stands at 535,246.

LH stock has decreased by -4.92% in the last month. The company shares reached their 1-month lowest point of $269.27 on 10/18/21. With the stock rallying to its 52-week high on 09/09/21, shares of the company touched a low of $192.79 and a high of $309.60 in 52 weeks. It has reached a new high 38 times so far this year and achieved 38.61% or $78.60 in price. In spite of this, the price is down -8.87% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Insider Transactions

38 days have passed since Laboratory Corporation of America Holdings (LH) last reported insider trading activity. van der Vaart Sandra D, who is EVP, Chief Legal Officer, most recently acquired $4,500 shares at $296.78 per share on Sep 15. In this transaction, the insider spent $1,335,510. EVP, Chief Legal Officer, van der Vaart Sandra D, disposed of 4,500 shares at a price of $266.56 on Jun 07. The insider now owns more than $1,199,520 worth of shares. Prior to that, CEO, Covance Drug Development Kirchgraber Paul R went on to Sale 2,500 shares at $276.55 each on May 06. An amount of $691,375 was transacted.

Valuation Metrics

Laboratory Corporation of America Holdings (LH) has a trailing price-to-earnings (P/E) ratio of 9.63, which compares with the 26.50 for the broader industry and 33.43 for the sector. In the last five years, Laboratory Corporation of America Holdings’s PE ratio has ranged between 56.48 and 8.724. The stock’s beta is 1.03. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1.68, the price-to-book (PB) ratio at 2.68, and the price-to-cash flow ratio at 9.73.

The quick ratio of Laboratory Corporation of America Holdings for the three months ended June 29 was 2.00, and the current ratio was 2.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.54 and a total debt to equity ratio of 0.54 for the quarter ending June 29. Laboratory Corporation of America Holdings’s EBITDA margin for the year ending June 29 is 27.15%, while its operating margin for the same period stands at 25.00%. Its gross profit as reported stood at $4.95 billion compared to revenue of $13.98 billion.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Laboratory Corporation of America Holdings’s return on assets was 14.50%. For the broader industry, ROE averaged -2.89 over the past year.

Earnings Surprise

For the three-month period that ended June 29, Laboratory Corporation of America Holdings had $5.42 billion in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $467.4 million in the quarter, while revenues of $769.6 million were grew 50.45%. The analyst consensus anticipated Laboratory Corporation of America Holdings’s latest quarter earnings to come in at $5.53 per share, but it turned out to be $6.13, a 10.80% surprise. For the quarter, EBITDA amounted to $891.2 million. Shareholders own equity worth $96.4 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Laboratory Corporation of America Holdings (LH) price momentum. RSI 9-day as of the close on 22 October was 57.23%, suggesting the stock is Neutral, with historical volatility in this time frame at 11.76%.

As of today, LH’s price is $278.19 +3.88% or $10.55 from its 5-day moving average. LH is currently trading -4.80% lower than its 20-day SMA and +7.07% higher than its 100-day SMA. However, the stock’s current price level is -6.11% below the SMA50 and +29.25% above the SMA200.

The stochastic %K and %D were 85.19% and 64.75%, respectively, and the average true range (ATR) was 5.29. With the 14-day stochastic at 94.78% and the average true range at 5.33, the RSI (14) stands at 49.85%. The stock has reached 4.01 on the 9-day MACD Oscillator while the 14-day reading was at 3.84.

Analyst Ratings

Argus upgraded Laboratory Corporation of America Holdings (NYSE: LH) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Hold. The consensus rating for Laboratory Corporation of America Holdings (LH) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell LH, while 1 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 15 others rate it as a “buy”.

What is LH’s price target for the next 12 months?

Analysts predict a range of price targets between $325.00 and $380.00, with a median target of $340.00. Taking a look at these predictions, the average price target given by analysts for Laboratory Corporation of America Holdings (LH) stock is $343.46.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam